Merck & Co., Inc. $MRK Holdings Cut by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. lowered its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 665,035 shares of the company’s stock after selling 65,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in Merck & Co., Inc. were worth $97,201,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in MRK. Fisher Asset Management LLC boosted its stake in Merck & Co., Inc. by 8.3% during the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock valued at $6,059,345,000 after buying an additional 3,183,169 shares during the period. Dimensional Fund Advisors LP grew its position in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after buying an additional 2,969,856 shares in the last quarter. Bank of America Corp DE increased its stake in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Merck & Co., Inc. by 263.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock worth $347,334,000 after acquiring an additional 1,959,778 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

MRK traded up $0.79 during midday trading on Friday, hitting $147.74. The stock had a trading volume of 6,504,320 shares, compared to its average volume of 9,885,298. The company has a market cap of $364.21 billion, a P/E ratio of 152.31, a price-to-earnings-growth ratio of 6.74 and a beta of 0.13. The business has a fifty day moving average of $146.16 and a 200 day moving average of $128.61. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. Merck & Co., Inc. has a 1 year low of $91.49 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the business earned $2.58 earnings per share. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.

Key Headlines Impacting Merck & Co., Inc.

These are some of the MRK headlines that stood out recently:

  • Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
  • Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
  • Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MRK. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Jefferies Financial Group boosted their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. The Goldman Sachs Group upped their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. Finally, Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $155.74.

Read Our Latest Research Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.